Dose-dependent pharmacokinetics of 1(2-deoxy-β-D-ribofuranosyl)-2,4-difluoro-5-iodobenzene: A potential mimic of 5-iodo-2′-deoxyuridine

Biopharmaceutics and Drug Disposition

Volumn 24, Issue 9, 2003, Pages 385-395

  Khalili, Panteha ^a   Naimi, Ebrahim ^a   Sun, Wei Yan ^a   Knaus, Edward E ^a   Wiebe, Leonard I ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

1UdR; Biliary excretion; C arly nucleosides; Dose dependent pharmacokinetics; Glucuronide metabolites; Sulfate metabolites

Indexed keywords

1 (2 DEOXY BETA DEXTRO RIBOFURANOSYL) 2,4 DIFLUORO 5 IODOBENZENE; GLUCURONIDE; IDOXURIDINE; IDOXURIDINE DERIVATIVE; NUCLEOSIDE DERIVATIVE; SULFATE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; BILIARY EXCRETION; CLINICAL STUDY; CONTROLLED STUDY; DATA ANALYSIS; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; DRUG STRUCTURE; DRUG SYNTHESIS; KIDNEY CLEARANCE; KIDNEY METABOLISM; MALE; NONHUMAN; NONLINEAR SYSTEM; PLASMA CLEARANCE; RAT; RAT STRAIN; SINGLE DRUG DOSE; STEADY STATE; URINARY EXCRETION;

ADMINISTRATION, ORAL; ANIMALS; AREA UNDER CURVE; BILE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOSE-RESPONSE RELATIONSHIP, DRUG; HALF-LIFE; IDOXURIDINE; INJECTIONS, INTRAVENOUS; LIVER; MALE; MOLECULAR MIMICRY; RATS; RATS, SPRAGUE-DAWLEY; RIBOSE; TIME FACTORS;

EID: 0347917304     PISSN: 01422782     EISSN: None     Source Type: Journal    
DOI: 10.1002/bdd.375     Document Type: Article

References (11)

1. Wang Z-X, Duan W, Wiebe LI, Balzarini J, De Clercq E, Knaus EE. Synthesis of 1-(2-deoxy-β-D-ribofuranosyl)-2,4-difluoro-5-substituted-benzene thymidine mimics, some related α anomers, and their evaluation as antiviral and anticancer agents. Nucleosides Nucleotides Nucleic Acids 2001; 20: 11-40.
2. Wang Z-X, Duan W, Wiebe LI, Balzarini J, De Clercq E, Knaus EE. Synthesis of 1-(2-deoxy-β-D-ribofuranosyl)-2,4-difluoro-5-substituted-benzenes: 'thymine replacement' analogs of thymidine for evaluation as anticancer and antiviral agents. Nucleosides Nucleotides Nucleic Acids 2001; 20: 41-58.
3. Khalili P, Naimi E, Knaus EE, Wiebe LI. Pharmacokinetics and metabolism of the novel synthetic C-nucleoside, 1-(2-deoxy-β-D-ribofuranosyl)-2,4-difiuoro-5-iodobenzene: a potential mimic of 5-iodo-2′-deoxyuridine. Biopharm Drug Dispos 2002; 23: 105-113.
4. Huang S-H, Remmel RP, Zimmerman CL. The bioavailability and nonlinear clearance of (-)-carbovir in the rat. Pharm Res 1991; 8: 739-743.
5. Evelo CTA, Versteegh JFM, Blaauboer BJ. Kinetics of the formation and secretion of the aniline metabolite 4-aminophenol and its conjugates by isolated rat hepatocytes. Xenobiotica 1984; 14: 409-416.
6. Lin JH. Dose-dependent pharmacokinetics: Experimental observations and theoretical considerations. Biopharm Drug Dispos 1994; 15: 1-31.
7. Kempf DJ, Marsh KC, Denissen JF, et al. ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in human. Proc Natl Acad Sci 1995; 92: 2484-2488.
8. Yeh KC, Stone JA, Carides AD, Rolan P, Woolf E, Ju WD. Simultaneous investigation of indinavir nonlinear pharmacokinetics and bioavailability in healthy volunteers using stable isotope labeling technique: study design and model-independent data analysis. J Pharm Sci 1999; 88: 568-573.
9. Rowland M, Tozer TN. Clinical Pharmacokinetics: Concepts and Applications, 3rd edn. Lea & Febiger: PA, USA: 1995.
10. Shargel L, Yu A. Applied Biopharmaceutics and Pharmacokinetics, 4th edn. Appleton & Lange: Stamford, Connecticut, 1999.
11. Stretcher BN. Pharmacokinetic optimization of antiretroviral therapy in patients with HIV infection. Clin Pharmacokinet 1995; 29: 46-65.